Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_assertion type Assertion NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_head.
- NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_assertion description "[This study was undertaken (1) to investigate the gene and protein expression of cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor-gamma (PPARgamma), interleukin-8 (IL-8), hepatocyte growth factor (HGF), gastrin, and its receptor (CCK-2) in the Barrett's epithelium; (2) to analyze the activity of NFkappaB in Barrett's esophagus with low-grade dysplasia; and (3) to assess the effects of PPARgamma ligand (ciglitazone) and gastrin on cell proliferation in the cell line derived from esophageal adenocarcinoma (OE-33).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_provenance.
- NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_assertion evidence source_evidence_curated NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_provenance.
- NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_assertion SIO_000772 15387324 NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_provenance.
- NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_assertion wasDerivedFrom ctd_human-20130708 NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_provenance.
- NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_assertion wasGeneratedBy ECO_0000218 NP16472.RABfgK11gYc6IcyLD-NkMOGRKm6drWnvLZoCzZ1PJa_O0130_provenance.